American Journal of Hypertension最新文献

{"title":"Factors Associated With Discussing High Blood Pressure Readings in Clinical Notes.","authors":"Cole G Chapman, Philip M Polgreen, Manish Suneja, Barry L Carter, Linnea A Polgreen","doi":"10.1093/ajh/hpae153","DOIUrl":"10.1093/ajh/hpae153","url":null,"abstract":"<p><strong>Background: </strong>Blood pressure (BP) is routinely measured and recorded at healthcare visits, but high BP (HBP) measurements are not always discussed in clinical notes. Our objective was to identify patient- and visit-level factors associated with discussion of HBP measurements in clinical notes, among patients without prior diagnosis of hypertension.</p><p><strong>Methods: </strong>Data from 2016 to 2022 for all patients with any BP record of 140/90 mmHg or greater were obtained from University of Iowa Hospitals and Clinics electronic medical records. Patients with any prior hypertension diagnosis were excluded. We used a multi-level regression model to evaluate differences in the rates of discussing HBP. The model included varying intercepts for visit specialty and non-varying slopes and intercepts for patient- and visit-level features.</p><p><strong>Results: </strong>The final sample included 278,766 outpatient visits for 27,423 patients, of which 61,739 visits had HBP. Only 31% of visits with HBP had associated clinical notes with a discussion of HBP. Even in primary-care-related clinics, HBP measurements were discussed in only 70% of visits. Factors associated with decreased odds of HBP being discussed in clinical notes included fever (OR: 0.46; 95%CI: 0.24-0.86) or external injury or pain (0.84; 0.79-0.90), and a larger number of comorbidities (6+: 0.27; 0.22-0.32). Discussion of HBP in clinical notes was more likely among visits of patients with prior visits where HBP was discussed in clinical notes (12.36; 11.75-13.01).</p><p><strong>Conclusions: </strong>We found that discussion of HBP is relatively uncommon. Increasing discussion of hypertension in clinical notes could decrease hypertension-related diagnostic inertia.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"225-232"},"PeriodicalIF":3.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obese Hypertensive Men Have Fasting Serum Concentrations of Leptin Similar to Those of Obese Normotensive Men.","authors":"Camilla L Asferg, Ulrik B Andersen, Jan Frystyk, Allan Linneberg, Paula L Hedley, Michael Christiansen, Jørgen L Jeppesen","doi":"10.1093/ajh/hpaf007","DOIUrl":"10.1093/ajh/hpaf007","url":null,"abstract":"<p><strong>Background: </strong>Leptin is a hormone that is secreted by the adipocytes. In the circulation, leptin levels are directly proportional to the body fat percentage. Studies have shown that higher leptin levels are associated with an increased risk of hypertension after adjusting for body mass index (BMI). Therefore, leptin has been proposed as a mediator of obesity-related hypertension. Whether leptin is associated with hypertension when controlling for body fat percentage remains unclear.</p><p><strong>Methods: </strong>We studied 103 obese men (BMI ≥ 30.0 kg/m2). All men were healthy and were medication-free. We measured blood pressure using 24-h ambulatory blood pressure (ABP) recordings. Hypertension was defined as 24-h systolic ABP ≥ 130 mm Hg and/or 24-h diastolic ABP ≥ 80 mm Hg, and normotension was defined as 24-h ABP < 130/80 mm Hg. We measured fasting serum leptin concentrations and used dual-energy X-ray absorptiometry scanning to determine body fat percentage.</p><p><strong>Results: </strong>Of the 103 obese men, 64 were hypertensive (24-h systolic ABP-mean ± standard deviation-137 ± 11 mg Hg and 24-h diastolic ABP 83 ± 6 mm Hg) and 40 were normotensive (24-h systolic ABP 117 ± 6 mg Hg and 24-h diastolic ABP 73 ± 4 mm Hg). The 2 groups had similar fasting serum leptin concentrations (median-interquartile range; 13.4 (5.7-36.1) µg/L vs. 13.4 (5.4-27.1) µg/L, P = 0.88) and total fat mass percentage (34.8 ± 4.5% vs. 34.0 ± 4.7%, P = 0.90).</p><p><strong>Conclusions: </strong>Obese hypertensive men have serum leptin concentrations similar to those of obese normotensive men with comparable body fat percentage measurements. This finding does not support leptin's candidacy as a mediator of obesity-related hypertension.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"233-239"},"PeriodicalIF":3.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142962008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood Pressure Phenotype Variations at Different Gestational Stages and Associated Pregnancy Risks.","authors":"Lushu Zuo, Yiwen Fang, Linjie Li, Hongli Duan, Jiying Wen, Qing Yang, Cha Han, Lijuan Lv, Xin Zhou","doi":"10.1093/ajh/hpaf038","DOIUrl":"https://doi.org/10.1093/ajh/hpaf038","url":null,"abstract":"<p><strong>Background: </strong>Hypertensive disorders of pregnancy (HDP) significantly increase the risk of adverse pregnancy outcomes (APOs). Blood pressure (BP) phenotypes, including masked hypertension (MH), white-coat hypertension (WCH), sustained hypertension (SH), and normotension, are identified through office BP (OBP) and ambulatory BP (ABP) monitoring. The proportion of BP phenotypes at different gestational age and their associations with APOs are not well understood.</p><p><strong>Methods and results: </strong>This retrospective study included 967 women at high risk or diagnosed with HDP who underwent OBP and ABP measurement at different gestational stages [0-19+6 (n=150), 20+0-29+6 (n=221), 30+0-32+6 (n=135), 33+0-35+6 (n=185), and ≥36+0 gestational weeks (GW) (n=276)]. Women with ABP monitored at 20+0-29+6 GW had the lowest BP levels corresponding to the highest prevalence of NT. Compared to OBP, hypertension determined by ABP demonstrated stronger and more consistent associations with APOs, defined as a composite of maternal (e.g., severe preeclampsia, preterm birth) and fetal (pregnancy loss and SGA infants) outcomes. SH was consistently associated with the highest risk for APOs, with risk decreasing as gestation advanced after 20+0 GW. MH was significantly associated with APOs, particularly between 30+0-32+6 GW. WCH had no association with fetal outcomes at any gestational stage.</p><p><strong>Conclusion: </strong>The associations between BP phenotypes and APOs differ across gestational stages. SH detected earlier in pregnancy carries the highest risks, while WCH is generally benign for fetal outcomes. These findings highlight the critical role of ABP monitoring in BP phenotyping and underscore the need for gestational-stage-specific diagnostic thresholds to enable tailored interventions and optimize APOs.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nighttime Systolic Blood Pressure a Major Factor of Retinal Vascular Caliber Changes in Patients With Newly Diagnosed Type 2 Diabetes Mellitus.","authors":"Barbara Nikolaidou, Areti Triantafyllou, Panagiota Anyfanti, Eleni Gavriilaki, Antonios Lazaridis, Panagiotis Dolgyras, Maria Gavriilaki, Anastasia Stoimeni, Konstantinos Mastrogiannis, Christina Trakatelli, Michael Doumas, Eugenia Gkaliagkousi","doi":"10.1093/ajh/hpaf004","DOIUrl":"10.1093/ajh/hpaf004","url":null,"abstract":"<p><strong>Background: </strong>Changes in retinal vessel caliber are crucial for detecting early retinopathy, a significant cause of blindness in individuals with Diabetes Mellitus type 2 (T2DM). This study aims to evaluate the changes in retinal vessel caliber and identify factors associated with these changes in recently diagnosed T2DM patients.</p><p><strong>Methods: </strong>The study included newly diagnosed T2DM patients (within 6 months of diagnosis) who were free of antidiabetic treatment (except metformin) and matched individuals based on age and blood pressure (BP). Data collected included somatometric measurements, BP (office and 24-h), hematological data, albuminuria (via 24-h urine collections), ten-year atherosclerotic cardiovascular disease risk (ASCVD score), endothelial dysfunction (measured by Asymmetric Dimethylarginine, ADMA), retinal microvascular changes, assessed as central retinal arteriolar equivalent (CRAE), central retinal venular equivalent (CRVE), and arteriovenous ratio (AVR) using specialized software on nonmydriatic fundus photographs.</p><p><strong>Results: </strong>The study involved 87 T2DM patients and 90 controls, aged 57±11 years. Key findings include no significant differences in CRAE, CRVE, and AVR between T2DM patients and controls. Age (P=0.019) and nighttime systolic BP (SBP) (P=0.002) were independent predictors of AVR. CRAE was independently associated with nighttime SBP (P=0.048). CRVE was independently associated with age (P=0.016), dipping (P=0.002), and smoking (P=0.018). In normotensive subjects, AVR was significantly lower in T2DM patients (P=0.035).</p><p><strong>Conclusions: </strong>The study concludes that increased nighttime SBP is a more critical factor than hyperglycemia in affecting retinal vascular caliber changes in newly diagnosed T2DM patients. This highlights the importance of managing nocturnal hypertension to prevent retinal damage in this patient population.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"217-224"},"PeriodicalIF":3.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142961987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypertension Is Too Important for Healthcare Professionals Alone to Try and Solve.","authors":"Robert D Brook, Phillip D Levy, James Brian Byrd","doi":"10.1093/ajh/hpaf009","DOIUrl":"10.1093/ajh/hpaf009","url":null,"abstract":"","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"203-205"},"PeriodicalIF":3.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Renal Medullary Bilirubin and Biliverdin Reductase in Angiotensin II-Dependent Hypertension.","authors":"Gertrude Arthur, Andrew R Wasson, Ross E Straughan, Heather A Drummond, David E Stec","doi":"10.1093/ajh/hpae150","DOIUrl":"10.1093/ajh/hpae150","url":null,"abstract":"<p><strong>Background: </strong>Increased circulating bilirubin attenuates angiotensin (Ang) II-induced hypertension and improves renal hemodynamics. However, the intrarenal mechanisms that mediate these effects are not known. The goal of the present study was to test the hypothesis that bilirubin generation in the renal medulla plays a protective role against Ang II-induced hypertension.</p><p><strong>Methods: </strong>Twenty-week-old male C57Bl/6J mice were implanted with intrarenal medullary interstitial (IRMI) catheters following unilateral nephrectomy. After this time, biliverdin IXα was specifically infused into the kidney (3.6 mg/day) for 3 days before implantation with an osmotic minipump delivering Ang II (1,000 ng/kg/min). BP was recorded for 3 days, 1 week after minipump infusion, in conscious mice. To further explore the antihypertensive role of renal medullary bilirubin generation, mice with specific deletion of biliverdin reductase-A (Blvra) in the thick ascending loop of Henle were generated. At 20 weeks, BlvraTALHKO and control mice (Blvrafl/fl) were infused with Ang II for 2 weeks.</p><p><strong>Results: </strong>IRMI infusion of biliverdin significantly decreased blood pressure compared with mice infused with vehicle (118 ± 4 vs. 158 ± 2 mmHg, p < 0.05). Angiotensin-II infusion resulted in significantly higher blood pressure measured in conscious mice 7 days after implantation in BlvraTALHKO as compared to Blvrafl/fl mice (152 ± 2 vs. 140 ± 3 mmHg, P < 0.05).</p><p><strong>Conclusions: </strong>Altogether, these findings show that medullary bilirubin and biliverdin reductase can improve hypertension and that mechanisms that increase bilirubin and biliverdin reductase in the renal medulla could be an effective approach to treat hypertension.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"240-247"},"PeriodicalIF":3.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911318/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Randomized Controlled Trial on the Efficacy and Safety of a Calcium-Channel Blocker and an Angiotensin-Converting Enzyme Inhibitor in Chinese and European Patients with Hypertension.","authors":"Wei Zhang, Chang-Yuan Liu, Grzegorz Bilo, Davide Soranna, Antonella Zambon, Konstantinos G Kyriakoulis, Anastasios Kollias, Isabella Ceravolo, Silvia Cassago, Martino F Pengo, Antonios Destounis, George S Stergiou, Ji-Guang Wang, Gianfranco Parati","doi":"10.1093/ajh/hpae152","DOIUrl":"10.1093/ajh/hpae152","url":null,"abstract":"<p><strong>Background: </strong>In a post hoc analysis of a multinational, randomized trial, we investigated whether the efficacy and safety of nifedipine-gastrointestinal therapeutic system (GITS) and ramipril differed between Chinese and European patients with hypertension.</p><p><strong>Methods: </strong>Previously treated (after 2-week washout) and untreated patients with clinic blood pressure (BP) ≥ 140/90 mmHg (systolic/diastolic), daytime ambulatory BP ≥ 135/85 mmHg and standard deviation of home systolic BP > 7 mmHg, and/or daytime BP > 12 mmHg were randomly assigned to treatment based on nifedipine-GITS 30 mg or ramipril 10 mg for 12 months. Clinic, ambulatory and home BP were measured at baseline, 10 weeks and 12 months after randomization.</p><p><strong>Results: </strong>A total of 67 Chinese and 101 European patients were analyzed and they differed in age (50.9 vs. 54.6 years, respectively), body mass index (24.5 vs. 27.0 kg/m2), clinic diastolic BP (87.9 vs. 92.5 mmHg), heart rate (75.0 vs. 70.8 beats/minute), and nighttime diastolic BP (79.3 vs. 75.9 mmHg) (all P < 0.05). However, within each ethnicity, patients were comparable for clinical characteristics between the nifedipine-GITS and ramipril groups (P > 0.05). In both the Chinese and European patients, BP was similarly reduced with nifedipine-GITS and ramipril, except that daytime systolic/diastolic BP reductions were 7.4/4.1 mmHg greater in the ramipril than nifedipine-GITS group in Chinese (P = 0.02). The safety profile differed between the Chinese and European patients (P for drug*ethnicity interaction ≤ 0.05) for all adverse events (lower incidence on nifedipine-GITS in Chinese), ankle edema (higher on nifedipine-GITS in Europeans), and dry cough (higher on ramipril in Chinese).</p><p><strong>Conclusion: </strong>In the Chinese and European patients with hypertension, nifedipine-GITS and ramipril had similar BP lowering efficacy, but different safety profile and tolerability.</p><p><strong>Clinical trials registration: </strong>Identifier at clinicaltrials.gov NCT02499822 (Registration date: 16 July 2015).</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":"248-256"},"PeriodicalIF":3.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating Proteomics and Mendelian Randomization to Identify New Therapeutic Targets.","authors":"Gaetano Santulli, Fahimeh Varzideh, Urna Kansakar, Stanislovas S Jankauskas, Scott Wilson, Pasquale Mone","doi":"10.1093/ajh/hpaf034","DOIUrl":"https://doi.org/10.1093/ajh/hpaf034","url":null,"abstract":"","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral losartan treatment improves microvascular endothelial function via nitric oxide-dependent mechanisms in women with a history of preeclampsia.","authors":"K S Schwartz, D I Jalal, A E Stanhewicz","doi":"10.1093/ajh/hpaf033","DOIUrl":"https://doi.org/10.1093/ajh/hpaf033","url":null,"abstract":"<p><strong>Background: </strong>Women with a history of preeclampsia are at increased risk of developing cardiovascular disease compared with women who had a healthy pregnancy. One potential mechanism underlying this increased risk is microvascular endothelial dysfunction, characterized by reduced nitric oxide (NO)-dependent dilation and is mediated, in part, by increased vasoconstrictor sensitivity to angiotensin II, which persists postpartum. We hypothesized that systemic angiotensin II type 1 receptor (AT1R) inhibition via once-daily oral losartan treatment would 1) improve endothelium- and NO-dependent dilation, and 2) reduce angiotensin II-mediated vasoconstriction, in the microvasculature of women with a history of preeclampsia.</p><p><strong>Methods: </strong>Eleven normotensive women, >12 weeks and ≤5 years postpartum, with a history of preeclampsia participated in a double-blind, placebo-controlled, crossover study. Following 6 weeks of placebo and losartan treatment (50 mg/day), we measured cutaneous vascular conductance responses to graded infusions of acetylcholine (ACh, 10-10-10-1M) alone or with 15mM NG nitro L-arginine methyl ester (L-NAME; NO-synthase inhibitor) to assess endothelium- and NO-dependent dilation, respectively. We also assessed microvascular vasoconstrictor responses to graded infusions of angiotensin II (10-20-10-4M) and norepinephrine (10-12-10-2M).</p><p><strong>Results: </strong>Losartan treatment increased endothelium- (P<0.001) and NO-dependent (P<0.016) vasodilation compared with placebo. Losartan treatment also reduced angiotensin II-mediated vasoconstriction (P<0.001) compared with placebo, but had no effect on norepinephrine-mediated vasoconstriction (P=0.46).</p><p><strong>Conclusions: </strong>These data suggest that systemic AT1R-inhibition with oral losartan is a viable, mechanism-specific approach to improve endothelial function and reduce vasoconstrictor sensitivity to angiotensin II in the microvasculature of healthy, normotensive women with a history of preeclampsia.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143613024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between metabolic syndrome and hyperuricemia: a systematic review and meta-analysis.","authors":"Jihuan Fan, Cuicui Bian, Jiapeng Wang, Xinyue Wang, Yanhua Cheng, Jie Lei","doi":"10.1093/ajh/hpaf031","DOIUrl":"https://doi.org/10.1093/ajh/hpaf031","url":null,"abstract":"<p><strong>Background: </strong>The main goal of this study was to conduct a meta-analysis and systematic review to examine the correlation between metabolic syndrome (MetS) and hyperuricemia.</p><p><strong>Methods: </strong>All studies available in PubMed, Cochrane Library, Embase, and Web of Science were obtained within the retrieval timeframe ending on December 9, 2023. Utilizing the Agency for Healthcare Research and Quality (AHRQ) and the Newcastle-Ottawa Scale (NOS), the included studies underwent quality appraisal, and Stata v14 software was employed for the subsequent data analysis.</p><p><strong>Results: </strong>A total of 40 studies, covering 214,091 patients, were selected based on specified inclusion and exclusion criteria. The analysis revealed a substantial association between MetS and hyperuricemia (Odds Ratio [OR] = 2.25, 95% Confidence interval [CI] 1.19-4.26, P<0.001). The metabolically abnormal overweight/obese group (MUHOWO) exhibited a heightened risk of hyperuricemia (OR = 3.54, 95%CI 2.66-4.71, P=0.002). Additionally, hyperuricemia increased the likelihood of developing MetS (OR = 2.13, 95%CI 1.63-2.79, P<0.001). Stratified by gender, hyperuricemia elevated the risk of MetS in both men (OR = 1.92, 95%CI 1.43-2.58, P<0.001) and women (OR = 2.13, 95%CI 1.62-2.8, P<0.001).</p><p><strong>Conclusions: </strong>This meta-analysis and systematic review robustly affirm a significant bidirectional association between MetS and hyperuricemia. The increased risk observed, especially in MUHOWO and across gender lines, underscores the clinical relevance. Addressing metabolic syndrome emerges as crucial in preventing and managing hyperuricemia, and vice versa. These findings offer valuable insights, urging further research into underlying mechanisms for more targeted interventions and personalized treatments in clinical practice.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}